title: Anaplastic thyroid cancer.
abstract: OBJECTIVE
  Anaplastic thyroid cancer (ATC) is a rare malignancy of the thyroid with a high mortality rate. Conventional therapy has not been effective. Several biological agents are being investigated. The purpose of the review is to highlight the current standards for treatment and review new targets for treating ATC.
  
  
  RESULTS
  Retrospective studies have led to formulation of guidelines for management, including those by the American Thyroid Association. An expansion in the understanding of the genetic mutations has led to several newer biological agents being tested to treat ATC. Aurora kinase inhibitors, PPAR γ agonists, and vascular targeting agents are some of the latest therapeutic agents that have shown promise and could become standard of therapy with further supporting research.
  
  
  CONCLUSIONS
  Further well coordinated preclinical and clinical research is needed to support the emerging treatments for ATC.
authors: aMemorial Sloan Kettering Cancer Center, New York bMercy Catholic Medical Center, Philadelphia, USA.
authors: Rohit
authors: R
authors: Ranganath
authors: Manish A
authors: MA
authors: Shah
authors: Ashok R
authors: AR
authors: Shah
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017408:Guidelines as Topic; D006801:Humans; D065646:Thyroid Carcinoma, Anaplastic / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents